Amarin Corp Plc (AMRN)

[Biobillionair]

Regarding Vascepa for PREVENTION of Alzheimer's:

The efficacy of drugs targeted to brain plaques in Alzheimer's patients has been called into question, although such drugs may still be effective for prophylaxis if given to individuals who have not yet developed clinical symptoms.[10] [11]

https://en.wikipedia.org/wiki/Bapineuzumab

Prophylaxis treatment for patient showing signs of brain amyloids is likely the indication to go after with Vascepa. This is due to side effect profile and low cost. High cost antibody's have more side effect and are much less likely to get the bang for the buck. Perhaps advanced cases should be studied using a combination Vascepa/antibody?

I am very bullish regarding Vascepa's Alzheimer's prospects now that the FDA change the approval bar for safe low cost drugs.

Statement from FDA Commissioner Scott Gottlieb, M.D. on advancing the development of novel treatments for neurological conditions; part of broader effort on modernizing FDA’s new drug review programs

https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm596897.htm




BB